Hormonal
Real-world use of semaglutide for weight loss (SEMA-WL) in adults with obesity results in median weight loss of 17% after >5 months of treatment, with nausea and constipation being the most common side effects.
If you have obesity and are considering semaglutide, expect significant weight loss (around 17% after 5+ months) but also common side effects like nausea and constipation. Most users find self-injection manageable, though some prefer a pill. Talk to your doctor about managing side effects and setting realistic expectations.
Self-reported weight loss corresponded to a median weight loss of 5.3% (IQR 3.2–8.5) for users treated with SEMA-WL for <3 months (24%, n = 115), 10% (IQR 8.2–14) for 3–5 months of treatment (17%, n = 82) and 17% (IQR 13–21) for those treated for >5 months (58%, n = 276).
Why this rating
Observational survey with self-reported data and potential selection bias.
Source
Survey among adult users of semaglutide for weight loss in Denmark: User characteristics, treatment expectations and experienced effects
Marc Sørensen et al. · Diabetes Obesity and Metabolism · 2025
DOI 10.1111/dom.16222
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →